中国医科大学学报

中国医科大学学报

中国医科大学学报 ›› 2012, Vol. 41 ›› Issue (1): 65–68.

• 临床医学 • 上一篇    下一篇

41例PET/CT检查发现颅外转移的Ⅳ期非小细胞肺癌治疗结果和预后分析

王天禄1, 宋颖秋2,李光2,党军2 , 姚雷2,白露2,李亚明3   

  1. (1.辽宁省肿瘤医院放疗科,沈阳110042;2.中国医科大学附属第一医院放疗科,沈阳110001;3.中国医科大学附属第一医院核医学科,沈阳110001)
  • 收稿日期:2012-09-19 修回日期:2012-09-19 出版日期:2012-01-01 发布日期:2012-09-21
  • 通讯作者: 李光,E-mail: liguang1963@yahoo.com.cn
  • 作者简介:王天禄(1974 -),男,主治医师,硕士 .E-mail:wangtianlu126@126.com
  • 基金资助:
    辽宁省科学技术计划项目(2006225007-5)

Outcome and Prognostic Factors for Survival in Stage Ⅳ Non-small Cell Lung Cancer Detected Extracranial Metastasis with PET/CT

WANG Tian-lu1, SONG Ying-qiu2, LI Guang2 , DANG Jun2, YAO Li2 ,BAI Lu2 , LI Ya-ming3   

  • Received:2012-09-19 Revised:2012-09-19 Online:2012-01-01 Published:2012-09-21

摘要: 目的 分析PET/CT检查发现颅外远处转移的Ⅳ期非小细胞肺癌(non-small-cell lung cancer , NSCLC)的治疗结果及预后因素。方法 对41例PET/CT定位扫描新发现有颅外远处转移的Ⅳ期NSCLC进行回顾性分析,采用Kaplan-Meier法计算其生存率并logrank法检验和单因素预后分析,采用Cox模型行多因素预后分析。结果 1、2年生存率分别为29.3%、9.8%,全组病例中位生存期10个月, 其中23例单发转移组患者中位生存期12个月,18例多发转移组患者中位生存期5个月, 2组间生存期差异有统计学意义(X2=15.889,P=0.000)。多因素分析结果显示影响Ⅳ期NSCLC预后因素有转移灶数、是否吸烟(X2=13.110、4.213,P=0.000、0.040)。结论 PET/CT检查发现颅外远处转移的Ⅳ期NSCLC患者的中位生存期达10个月,有优于以往报道的Ⅳ期NSCLC患者治疗结果的趋势。转移灶数目、是否吸烟是影响其生存的显著预后因素。

关键词: 体层摄影术,正电子发射, 非小细胞肺癌, 转移, 预后, 体层摄影术, 正电子发射, 非小细胞肺癌, 转移, 预后

Abstract: Objective To investigate outcome and prognostic factors for survival in Stage Ⅳ non-small-cell lung cancer (NSCLC) detected extracranial metastasis with PET/CT. Methods PET/CT (Positron Emission Tomography/Computed Tomography) scanning was performed in pathologically proven NSCLC patients for radical radiotherapy. PET/CT identified previously undetected extracranial distant metastatic disease in 41 patients. These Stage Ⅳ NSCLC were included in this study. The impact of related prognostic factors on survival was evaluated by univariate and multivariate analyses. Results The overall 1-year and 2-year survival rate was 29.3% and 9.8% respectively, with a median survival time of 10 months, 12 months for 23 patients with single PET/CT–detected metastasis and 5 months for 18 patients with multiple metastasis(X2=15.889,P=0.000). PET/CT–detected metastasis at multivariate analysis, metastasis number, cigarette smoking status were significant prognostic factors(X2=13.110、4.213,P=0.000、0.040). Conclusions Patients in this study who were found by PET/CT to have stage Ⅳ NSCLC disease had a median survival time of 10 months, which was superior to the rate of survival reported in most published series of patients with stage Ⅳ NSCLC . Metastasis number, cigarette smoking status were significant prognostic factors on survival in patients with stage Ⅳ NSCLC detected extracranial metastasis with PET/CT.

Key words: PET/CT, non-small-cell lung cancer, metastasis, prognosis, PET/CT, non-small-cell lung cancer, metastasis, prognosis

[1] Reck M. Current approaches in chemotherapy of advanced and metastatic non-small cell lung cancer (NSCLC)[J]. Anticancer Res,2005,25(3A):1501-1506.
[2] Schiller JH, Harrington D, Belani CP, et al. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med,2002,346(2):92-98.
[3] Ung YC, Maziak DE, Vanderveen JA, et al. Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review[J]. J Natl Cancer Inst,2007,99(23):1753-1767.
[4] Heron DE, Andrade RS, Beriwal S, et al. PET-CT in radiation oncology: the impact on diagnosis, treatment planning, and assessment of treatment response[J]. Am J Clin Oncol,2008,31(4):352-362.
[5] Goldstraw P, Crowley J, Chansky K, et al. International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours[J]. J Thorac Oncol,2007,706-714.
[6] Weber WA, Dietlein M, Hellwig D, et al. PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer[J]. Nuklearmedizin,2003,42(4):135-144.
[7] Mac Manus MP, Wong K, Hicks RJ, et al. Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center[J]. Int J Radiat Oncol Biol Phys,2002,52(2):351-61.
[8] MacManus MR, Hicks R, Fisher R, et al. FDG-PET-detected extracranial metastasis in patients with non-small cell lung cancer undergoing staging for surgery or radical radiotherapy—survival correlates with metastatic disease burden[J]. Acta Oncol,2003,42(1):48-54.
[9] Oh Y, Taylor S, Bekele BN, et al. Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases[J]. Cancer,2009,115(13):2930-8.
[10] Bryant A, Cerfolio RJ. Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer[J]. Chest,2007,132(1):185-92. Epub 2007 Jun 15.
[11] Kawaguchi T, Takada M, Kubo A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC[J]. J Thorac Oncol,2010 ,5(5):620-30.
[1] 徐国帅, 蔡相军, 陈江波, 吕庆, 刘洪涛. AEG-1和CHD5在胃癌中的表达及其临床意义[J]. 中国医科大学学报, 2018, 47(9): 797-802.
[2] 王倩文, 徐振华, 王志静, 苏荣健, 陈学军, 谷艳娇. 葡萄糖调节蛋白78对L858R突变的非小细胞肺癌erlotinib敏感性的影响[J]. 中国医科大学学报, 2018, 47(8): 701-704.
[3] 马艳梅, 常箫匀. 结直肠癌患者围手术期肠内外联合营养支持与预后的关系[J]. 中国医科大学学报, 2018, 47(7): 604-608.
[4] 姜文娟, 刘文静, 李晓曦, 沈雪莉. 1例急性原发性胼胝体变性病例的回顾分析[J]. 中国医科大学学报, 2018, 47(7): 657-659.
[5] 芦婷婷, 王治博. 术前血浆纤维蛋白原和D-二聚体水平与结直肠癌预后的关系[J]. 中国医科大学学报, 2018, 47(6): 513-518.
[6] 武佳科, 田春阳, 何东旭, 宋佳, 于彤彤, 孙志军, 孙兆青. 休克指数对行经皮冠状动脉介入治疗的急性心肌梗死患者长期预后的预测价值[J]. 中国医科大学学报, 2018, 47(6): 522-526.
[7] 刘晓, 王彤, 蒋怡芳, 王媛. 病原学阳性与阴性的医院获得性肺炎患者临床特征及预后比较[J]. 中国医科大学学报, 2018, 47(5): 406-410,414.
[8] 俞达辉, 吴道立, 袁冲, 褚文炎. 癌组织中CD45RO表达水平与肺腺癌患者临床病理特征及生存率的关联分析[J]. 中国医科大学学报, 2018, 47(5): 448-453.
[9] 邵洋, 胡延平, 刘勇. 慢性淋巴细胞白血病患者长链非编码RNA RP5-180C18.1的表达及其预后评价作用[J]. 中国医科大学学报, 2018, 47(4): 341-345.
[10] 范一博, 车晓芳, 赵欢, 胡雪君, 曲秀娟, 刘云鹏. microRNA-1183通过抑制CBL-B的表达促进胃癌细胞的增殖及转移[J]. 中国医科大学学报, 2018, 47(3): 202-205,211.
[11] 张苏宁, 刘宗昂. 小细胞肺癌中DBC1的表达及预后相关性研究[J]. 中国医科大学学报, 2018, 47(3): 222-225.
[12] 王鸾, 蔡雪, 赵敏. 急性百草枯中毒死亡危险因素分析[J]. 中国医科大学学报, 2018, 47(3): 237-239,243.
[13] 李蕙伊, 刘畅, 赵洋子, 曾仁庆, 甘淼, 王涛, 于诗源, 崇巍. 急诊科成人创伤患者院内死亡危险因素分析[J]. 中国医科大学学报, 2018, 47(2): 128-131.
[14] 杜国强, 王瑾, 柳斌. 扁桃体滤泡树突状细胞肉瘤伴转移1例报告及文献复习[J]. 中国医科大学学报, 2018, 47(2): 180-182.
[15] 李冬阳, 李智, 曲晶磊, 曲秀娟, 刘云鹏. NFκB活化受体因子在胃癌中的表达及临床意义[J]. 中国医科大学学报, 2018, 47(10): 881-885,890.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!

中国医科大学学报版权所有©2018

未经允许,严禁擅自转载本站图文资料

地址:中国 沈阳市沈北新区蒲河路77号 110122

辽ICP备05014850

JOURNAL OF CHINA MEDICAL UNIVERSITY

ADDRESS: NO.77 PUHE ROAD

SHENYANG NORTH NEW AREA, SHENYANG

LIAONING PROVINCE, P.R. CHINA